<DOC>
	<DOC>NCT02573740</DOC>
	<brief_summary>This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose study of ABT-957 in participants with mild Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) due to AD.</brief_summary>
	<brief_title>Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Female participants must have negative results for pregnancy test performed on a serum sample obtained at Screening Body Mass Index is 18.0 to 35.0 at Screening Meets the National Institute on Aging and the Alzheimer's Association (NIAAA) criteria for probable Alzheimer's disease (AD). Meets the NIAAA core clinical criteria for Mild Cognitive Impairment due to AD Use of any strong inhibitors of drug metabolizing enzymes within 30 days prior to study drug administration Consumption of alcohol within 24 hours prior to study drug administration Positive screen for nonprescribed drugs of abuse or alcohol The participant has clinically significant abnormal laboratory values at Screening as determined by the investigator History of a drug or alcohol abuse within 6 months prior to study drug administration Current diagnosis of major depression or other major psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Alzheimer's Disease</keyword>
</DOC>